Ophthalmic Consultants of Boston provides eye care services, including cataract surgery, LASIK, and retinal care. The practice is self-described as a multi-specialty ophthalmology practice with a history of innovation since 1969.

Ophthalmic Consultants of Boston

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Shwen Gwee

Johann Rudolf

Joerg Reinhardt

Alexander Clavel

Novartis AG

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc.

RetinAI is a technology company that specializes in creating a data management platform integrated with AI modules, designed to improve understanding of patients' diseases and outcomes through enhanced insights and knowledge.

Metric
Company Name	Ophthalmic Consultants of Boston	Novartis AG	Ocular Therapeutix, Inc.	RetinAI
Symbol		NOVN	OCUL
MSH ID	COM:EYEBOSTON	COM:NOVARTIS	COM:OCUTX	COM:RETINAI
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services		Healthcare	Healthcare & Health Services
Industry	Ophthalmology		Biotechnology	Healthcare Technology
Country	US	CH	US	CH
Stage				Series B
Employee Count		101.70K	267	38
Website	eyeboston.com	novartis.com	ocutx.com	retinai.com
LinkedIn		novartis	ocular-therapeutix-inc	retinai
Founders

Metric
Market Cap	220.95B	1.11B
Enterprise Value
Monthly Web Traffic			9.75K
Web Traffic Growth			0.67
Valuation
Raised Capital			7.80M

Metric
Revenue	46.66B	58.44M
Revenue (LTM)
Revenue (NTM)
Gross Profit	34.19B	53.16M
EBITDA	18.47B	-79.40M
Operating Income	9.77B	-82.38M
Net Income	14.85B	-80.74M
EPS		-0.94
Diluted EPS		-0.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.75	0.91
Operating Profit Margin	0.25	-1.41
EBITDA Margin	0.40	-1.36
Net Profit Margin	0.33	-1.49
Return on Equity	0.39	-0.63
Return on Assets	0.17	-0.21
Return on Capital Employed	0.17	-0.18

COM:EYEBOSTON

Ophthalmic Consultants of Boston

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	14.33	-5.67
P/B Ratio	4.56	50.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.83	29.00
EV Multiple	11.29	-10.81

Metric
Days Sales Outstanding	67.09	149.52
Days Payables Outstanding	124.77	296.28
Days Inventory Outstanding	169.11	174.21
Operating Cycle	232.40	347.24
Cash Conversion Cycle	110.44	106.71
Asset Turnover	0.53	0.23

Metric
Operating Cash Flow	14.46B	-70.23M
Free Cash Flow	11.71B	-76.32M
Cash Flow to Debt	0.55	-0.85
Operating Cash Flow/Sales	0.31	-1.12
Free Cash Flow Yield	0.05	-0.13

Metric
Cash & Equivalents	13.39B	195.96M
Accounts Receivable	-1.50B	-4.85M
Inventory	5.91B	2.31M
Goodwill	23.34B
Debt to Capitalization	0.41	0.46
Debt to Assets	0.26	0.51
Current Ratio	1.16	4.03
Quick Ratio	0.88	21.29

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	0.31
R&D to Revenue	0.23	1.01
SG&A to Revenue		0.60